Figures
- FIGURE 1
Flowchart depicting the total number of patients with available electronic health records (EHRs), the number of patients with asthma, the number of patients diagnosed with coronavirus disease 2019 (COVID-19), and of those, the number of hospitalisations after diagnosis during the study period (January 1 to May 10, 2020). All percentage values are computed in relation to the level immediately above.
Tables
- TABLE 1
Demographic and clinical characteristics of patients with asthma with/without coronavirus disease 2019 (COVID-19)
Asthma Asthma without COVID-19 Asthma with COVID-19 OR (95% CI) p-value# Patients n 71 182 70 176 1006 Age years 42±24 41±24 55±20 <0.001 Female 59 59 66 1.34 (1.18–1.54) <0.001 Tobacco use 10 9 11 1.25 (1.03–1.53) 00.02 Comorbidities Arterial hypertension 24 24 39 2.02 (1.78–2.30) <0.001 Dyslipidaemia 17 17 26 1.72 (1.49–1.98) <0.001 Diabetes mellitus 11 10 16 1.72 (1.45–2.03) <0.001 Obesity 10 10 13 1.35 (1.12–1.62) <0.001 Rhinitis 33 33 17 0.42 (0.35–0.49) <0.001 Eczema 7 7 1 0.50 (0.40–0.76) <0.001 Data are presented as mean±sd or %, unless otherwise stated. #: patients with asthma with COVID-19 versus patients with asthma without COVID-19.
- TABLE 2
Demographic and clinical characteristics of patients with asthma and coronavirus disease 2019 (COVID-19) who required hospital admission
Asthma+COVID-19 Asthma+COVID-19
non-hospitalisedAsthma+COVID-19
hospitalisedOR (95% CI) p-value# Patients n 1006 743 263 Age years 55±20 52±20 63±18 <0.001 Female 66 67 61 0.76 (0.57–1.02) 0.07 Tobacco use 7 7 6 0.69 (0.37–1.29) 0.29 Comorbidities Arterial hypertension 39 34 54 2.27 (1.71–3.03) <0.001 Dyslipidaemia 27 21 38 2.31 (1.70–3.13) <0.001 Diabetes mellitus 15 13 21 1.76 (1.22–2.54) 0.002 Obesity 13 12 18 1.60 (1.09–2.35) 0.02 Data are presented as mean±sd or %, unless otherwise stated. #: non-hospitalised patients versus hospitalised patients.
- TABLE 3
Treatment of patients with asthma and coronavirus disease 2019 (COVID-19): inhaled corticosteroids (ICS) and biologics in hospitalised versus non-hospitalised patients between January 1 and May 10, 2020
Patients Asthma+COVID-19 Asthma+COVID-19
hospitalisedp-value Patients with asthma 71 182 1006 263 Asthma + ≤1 ICS 42 171 (59.23% of asthmatic patients) 619 127 <0.001 Asthma + ≤1 biologic# 865 (1.21% of asthmatic patients) 18 2 Omalizumab 641 9 0 Mepolizumab 308 7 2 Benralizumab 98 2 0 Reslizumab 26 1 0 Data are presented as n, unless otherwise stated. #: 54% of the patients treated with mepolizumab had been treated previously with omalizumab; 65% of patients treated with benralizumab had been treated previously with omalizumab and 35% with mepolizumab. Most of the patients treated with reslizumab had been treated previously with omalizumab and mepolizumab.
- TABLE 4
In-hospital mortality in asthmatic patients with/without coronavirus disease 2019 (COVID-19)
Asthma with COVID-19 Asthma without COVID-19 OR (95% CI) p-value Age years 78±17 76±17 <0.001 Female 61 71 0.64 (0.56–0.73) Mortality 2.29 0.54 2.29 (4.35–6.66) Data are presented as mean±sd or %, unless otherwise stated.
Supplementary Material
Please note: supplementary material is not edited by the Editorial Office, and is uploaded as it has been supplied by the author.
Supplementary material ERJ-03142-2020.SUPPLEMENT
Supplementary Material
This one-page PDF can be shared freely online.
Shareable PDF ERJ-03142-2020.Shareable
